27638646|t|Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories
27638646|a|There is a great need for improved diagnostic and prognostic accuracy of potential cardiac toxicity in drug development. This study reports the evaluation of several commercially available biomarker kits by 3 institutions (SRI, Eli Lilly, and Pfizer) for the discrimination between myocardial degeneration / necrosis and cardiac hypertrophy as well as the assessment of the interlaboratory and interplatform variation in results. Serum concentrations of natriuretic peptides (N-terminal pro-atrial natriuretic peptide [NT-proANP] and N-terminal pro-brain natriuretic peptide [NT-proBNP]), cardiac and skeletal troponins (cTnI, cTnT, and sTnI), myosin light chain 3 (Myl3), and fatty acid binding protein 3 (FABP3) were assessed in rats treated with minoxidil (MNX) and isoproterenol (ISO). MNX caused increased heart -to- body weight ratios and prominent elevations in NT-proANP and NT-proBNP concentrations detected at 24-hr postdose without elevation in troponins, Myl3, or FABP3 and with no abnormal histopathological findings. ISO caused ventricular leukocyte infiltration, myocyte fibrosis, and necrosis with increased concentrations of the natriuretic peptides, cardiac troponins, and Myl3. These results reinforce the advantages of a multimarker strategy in elucidating the underlying cause of cardiac insult and detecting myocardial tissue damage at 24-hr posttreatment. The interlaboratory and interplatform comparison analyses also showed that the data obtained from different laboratories and platforms are highly correlated and reproducible, making these biomarkers widely applicable in preclinical studies.
27638646	0	10	Evaluation	T052	C1516048
27638646	14	30	Cardiac Toxicity	T037	C0876994
27638646	31	41	Biomarkers	T201	C0005516
27638646	45	49	Rats	T015	C0034693
27638646	65	77	Laboratories	T073,T093	C0022877
27638646	104	112	improved	T033	C0184511
27638646	113	123	diagnostic	T080	C0598285
27638646	128	138	prognostic	T170	C0220901
27638646	139	147	accuracy	T080	C0443131
27638646	161	177	cardiac toxicity	T037	C0876994
27638646	181	197	drug development	T091	C0872152
27638646	204	209	study	T062	C2603343
27638646	210	217	reports	T062	C0011000
27638646	222	232	evaluation	T052	C1516048
27638646	257	266	available	T169	C0470187
27638646	267	281	biomarker kits	T201	C0005516
27638646	287	299	institutions	T093	C2607850
27638646	301	304	SRI	T093	C2607850
27638646	306	315	Eli Lilly	T093	C0331851
27638646	321	327	Pfizer	T093	C0331888
27638646	360	383	myocardial degeneration	T046	C0027046
27638646	386	394	necrosis	T047	C1442837
27638646	399	418	cardiac hypertrophy	T046	C1383860
27638646	434	444	assessment	T052	C1516048
27638646	452	467	interlaboratory	T080	C2986928
27638646	472	485	interplatform	T080	C0205556
27638646	486	495	variation	T080	C0205419
27638646	499	506	results	T169	C1274040
27638646	508	528	Serum concentrations	T081	C0683149
27638646	532	552	natriuretic peptides	T116,T121,T125	C1144709
27638646	554	595	N-terminal pro-atrial natriuretic peptide	T116,T123	C0027481
27638646	597	606	NT-proANP	T116,T123	C0027481
27638646	612	652	N-terminal pro-brain natriuretic peptide	T116,T123	C0754710
27638646	654	663	NT-proBNP	T116,T123	C0754710
27638646	667	674	cardiac	T023	C0018787
27638646	679	687	skeletal	T082	C0521324
27638646	688	697	troponins	T116,T123	C0041199
27638646	699	703	cTnI	T116,T123	C1305957
27638646	705	709	cTnT	T116,T123	C3538889
27638646	715	719	sTnI	T116,T123	C0033684
27638646	722	742	myosin light chain 3	T116,T123	C0027108
27638646	744	748	Myl3	T116,T123	C0027108
27638646	755	783	fatty acid binding protein 3	T116,T123	C1721418
27638646	785	790	FABP3	T116,T123	C1721418
27638646	797	805	assessed	T052	C1516048
27638646	809	813	rats	T015	C0034693
27638646	814	821	treated	T169	C1522326
27638646	827	836	minoxidil	T109,T121	C0026196
27638646	838	841	MNX	T109,T121	C0026196
27638646	847	860	isoproterenol	T109,T121	C0022245
27638646	862	865	ISO	T109,T121	C0022245
27638646	868	871	MNX	T109,T121	C0026196
27638646	879	888	increased	T081	C0205217
27638646	889	894	heart	T023	C0018787
27638646	900	911	body weight	T032	C0005910
27638646	912	918	ratios	T081	C0456603
27638646	933	943	elevations	T082	C0702240
27638646	947	956	NT-proANP	T116,T123	C0027481
27638646	961	970	NT-proBNP	T116,T123	C0754710
27638646	971	985	concentrations	T081	C1446561
27638646	986	994	detected	T033	C0442726
27638646	1004	1012	postdose	T079	C0439568
27638646	1021	1030	elevation	T082	C0702240
27638646	1034	1043	troponins	T116,T123	C0041199
27638646	1045	1049	Myl3	T116,T123	C0027108
27638646	1054	1059	FABP3	T116,T123	C1721418
27638646	1069	1071	no	T033	C1513916
27638646	1072	1080	abnormal	T033	C0205161
27638646	1081	1098	histopathological	T169	C0243140
27638646	1099	1107	findings	T033	C0243095
27638646	1109	1112	ISO	T109,T121	C0022245
27638646	1120	1131	ventricular	T082	C1522565
27638646	1132	1154	leukocyte infiltration	T033	C0333361
27638646	1156	1172	myocyte fibrosis	T046	C0151654
27638646	1178	1186	necrosis	T042	C0027540
27638646	1192	1201	increased	T081	C0205217
27638646	1202	1216	concentrations	T081	C1446561
27638646	1224	1244	natriuretic peptides	T116,T121,T125	C1144709
27638646	1246	1253	cardiac	T023	C0018787
27638646	1254	1263	troponins	T116,T123	C0041199
27638646	1269	1273	Myl3	T116,T123	C0027108
27638646	1281	1288	results	T169	C1274040
27638646	1379	1393	cardiac insult	T047	C0018799
27638646	1398	1407	detecting	T033	C0442726
27638646	1408	1418	myocardial	T024	C0027061
27638646	1419	1432	tissue damage	T037	C0010957
27638646	1442	1455	posttreatment	T079	C2709088
27638646	1461	1476	interlaboratory	T080	C2986928
27638646	1481	1494	interplatform	T080	C0205556
27638646	1495	1505	comparison	T052	C1707455
27638646	1506	1514	analyses	T062	C0936012
27638646	1536	1540	data	T078	C1511726
27638646	1565	1577	laboratories	T073,T093	C0022877
27638646	1582	1591	platforms	T080	C0205556
27638646	1603	1613	correlated	T080	C1707520
27638646	1645	1655	biomarkers	T201	C0005516
27638646	1663	1673	applicable	T080	C1706839
27638646	1677	1696	preclinical studies	T062	C1709631